RxDoctor Payments Data

Ryan Baker, MD

Family Medicine · St Petersburg, FLNPI 1164650974

Payments from drug & device makers

$9,239in general payments, 2019–2025

Across 18 payments — averaging $513.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Corporation$9K
  • UCB, Inc.$125
  • Novo Nordisk$91
  • Dexcom, Inc.$90
  • GSK$37
  • Abbott$35
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,239 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$105,994
Medicare patients
187
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$89,363
EliquisApixaban68$80,290
MounjaroTirzepatide34$40,546
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,899
FarxigaDapagliflozin Propanediol13$21,934
XareltoRivaroxaban21$20,163
JardianceEmpagliflozin13$19,791
Breo ElliptaFluticasone/Vilanterol26$17,024
BrilintaTicagrelor19$16,793
ProzacFluoxetine Hcl26$10,811
Aimovig AutoinjectorErenumab-Aooe13$9,359
SymbicortBudesonide/Formoterol Fumarate18$6,010
Atorvastatin Calcium704$4,787
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,680
Albuterol Sulfate HfaAlbuterol Sulfate162$3,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$91$90,21878 claims
AstraZenecaFarxiga, Brilinta, Symbicort$16$44,73650 claims
GSKTrelegy Ellipta, Breo Ellipta$37$41,92256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →